Biosearch Technologies Licenses Access to new CDC “PDM” H1N1 Signatures
News Nov 19, 2010
Biosearch Technologies, Inc. (Biosearch) has announced that the company has licensed access to the new “pdm” H1N1 signatures from Centers for Disease Control and Prevention (CDC). The new “pdm” panel is optimized to achieve enhanced sensitivity and specificity for H1N1 specimen.
Responding to the outbreak of the Novel 2009 H1N1 and concurrently circulating “Seasonal” Influenza A (A/H1N1, H3N2) and B viruses in April of 2009, CDC designed and validated molecular diagnostic probes and primers (“signatures”) used in real-time RT-PCR detection assays.
Subsequent molecular and antigenic evolution associated with the geographical spread of Novel 2009 H1N1 influenza viruses has prompted CDC to design and validate new “pdm” molecular signatures. These new “pdm” signatures qualitatively detect currently circulating Novel 2009 H1N1 and demonstrate improved performance over the probe and primer sequences previously published on the World Health Organization’s (WHO) website.
“Today’s announcement advances Biosearch Technologies’ ardent support for CDC in emerging and actionable respiratory assays. Biosearch is dedicated in the pursuit of improved public health surveillance and disease prevention,” comments Marc Beal, Director of Corporate Development at Biosearch Technologies. “As licensors of CDC influenza signatures and as the inventors of BHQ® (Black Hole Quencher®) technology, Biosearch will provide access to 5’-Nuclease BHQ probes that meet CDC design and manufacturing specifications for PDM Novel 2009 H1N1 testing labs around the world.”
Biosearch was the first to license Influenza signatures from CDC, which conferred rights to Biosearch under the CDC patents to manufacture and sell dual-labeled probes and primers bearing the Novel 2009 H1N1 and Influenza A sub-typing signatures.